Efficacy and safety of the dual SGLT1 and SGLT2 inhibitor JP-2266 in Type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 2 study (Diabetes Metab J, published online July 29, 2026)

Diabetes & Metabolism · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles